By Susan Moench, PhD, PA-C
Results of an exploratory analysis showed longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in women with recurrent ovarian cancer treated with maintenance use of the poly(ADP-ribose) polymerase (PARP) inhibitor, … Read more
By Diana Swift
Population screening found to be cost-effective for higher income countries
Screening entire populations of women for mutations in breast and ovarian cancer susceptibility genes could prevent hundreds of thousands of cases in the U.S., and millions globally, … Read more
By Stand Up To Cancer
Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don’t get tested. A collaborative Stand Up … Read more
By Liam Davenport
Women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation could see their survival extended by over a year by maintenance therapy with the PARP-inihibitor olaparib (Lynparza, AstraZeneca).
The new overall survival (OS) data come … Read more
By Cancer Research UK
A genetic study has found evidence to suggest that women who take statins in the long term could be less likely to develop ovarian cancer, according to new research funded by Cancer Research UK published today … Read more
By Susan Moench, PhD, PA-C
A central tenant of a recently issued American Society of Clinical Oncology (ASCO) guideline is that all women with a diagnosis of epithelial ovarian cancer should be offered testing for specific germline mutations associated with … Read more
By Wayne Kuznar
The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more
By Dave Levitan
The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more
By Dave Levitan
The combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and immune checkpoint inhibition with tislelizumab was well tolerated and showed promising anti-tumor activity in a phase I trial of patients with multiple solid tumor types, according to … Read more
By Kristen Monaco
Researchers advocate for increased hormone therapy for high-risk women.
Bone health suffered in women with a BRCA mutation who underwent preventive oophorectomy, Canadian researchers reported.
Premenopausal women with the BRCA1 or BRCA2 mutation experienced a significant decline … Read more
By Leah Lawrence
In addition to putting carriers at increased risk for breast and ovarian cancers, BRCA2 germline mutations carriers are also at increased risk for pediatric and adolescent non-Hodgkin lymphoma (NHL), according to data from the SJLIFE study.… Read more
By Amirah Al Idrus
PARP inhibitors have transformed treatment for breast and ovarian cancers, but their use has been limited to the small proportion of patients who have BRCA mutations. New research out of UT Southwestern Medical Center has uncovered … Read more
By Colin C. Pritchard
People of all sexes can have risk genes that are often assumed to affect only women. Renaming the syndrome should aid cancer prevention and treatment, argues Colin C. Pritchard.
I recently had a conversation with my … Read more
By Dave Levitan
An analysis of the phase III SOLO1 trial found no new safety signals when the PARP inhibitor olaparib was given as maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation. Nausea, fatigue, … Read more
Patients with BRCA-mutated, platinum-sensitive relapsed ovarian cancer derived significant clinical benefit from treatment with olaparib monotherapy compared with treatment of physician’s choice, according to the results of the SOLO3 trial, a US Food and Drug Administration … Read more
By Ian Ingram
Benefit seen across all subgroups for patients with platinum-sensitive disease.
Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more
By Kristin Jenkins
The presence of a BRCA germ line mutation in patients with invasive epithelial ovarian cancer may confer a short-term survival advantage, but is not associated with a reduction in long-term mortality, researchers found.
A follow-up study comparing … Read more
By Dave Levitan
Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.
“Although most … Read more
By Krista Conger
A large study of women with breast and ovarian cancer has revealed significant gaps between national guidelines for genetic testing and actual testing practices, according to researchers from Stanford and five other institutions.
Fewer than a quarter … Read more
By Julia Karow
A study led by researchers at Invitae has found that 23andMe’s direct-to-consumer BRCA test, which tests for three common variants in the BRCA1 and BRCA2 genes and is authorized by the US Food and Drug Administration, misses … Read more
